Seagen Inc - Company Profile
Powered by 
All the data and insights you need on Seagen Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Seagen Inc Strategy Report
- Understand Seagen Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Seagen Inc (Seagen), formerly Seattle Genetics Inc, is a biotechnology company focused on the discovery, development, and commercialization of monoclonal antibody-based therapies for the treatment of cancer. The company markets antibody-drug conjugates (ADCs) designed to target specific types of cancer. These includes Adcetris (brentuximab vedotin), for the treatment of Hodgkin’s lymphoma, T-cell lymphomas, and CD30 expressing lymphomas; Padcevtm (enfortumab vedotin-ejfv) for metastatic urothelial cancers; Tukysa (tucatinib) for the treatment of metastatic HER2-positive breast cancers, and Tivdak (tisotumab vedotin-tftv) for the treatment of certain metastatic cervical cancers. The company’s pipeline consists of novel therapies for addressing the unmet medical needs in blood-related cancers and solid tumors. Seagen products and pipeline are based on ADC technology and SEA technology which targets monoclonal antibodies and delivers agents for killing cancer cells. The company sells its products through specialty distributors. Seagen is headquartered in Bothell, Washington, the US.
Headquarters
United States of America
Address
Building 3, 21717 30th Drive Se, Bothell, Washington, 98021
Website
www.seagen.com
Telephone
1 425 5274000
No of Employees
3,256
Industry
Pharmaceuticals and Healthcare
Revenue (2022)
$2.0B
Seagen Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| - | Adcetris |
| Adcetris (brentuximab vedotin): | Padcev |
| Hodgkin lymphoma | Tukysa |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In September, the company entered into an agreement with Nurix Therapeutics, Inc. to advance a new class of medicines called Degrader-Antibody Conjugates for use in cancer. |
| 2023 | Contracts/Agreements | In August, the company signed a contract with Skanska to construct a 25,000 square meter biomanufacturing facility for the global biotechnology company. |
| 2023 | Regulatory Approval | In April, the company and Astellas Pharma Inc announced the U.S. Food and Drug Administration granted PADCEV (enfortumab vedotin-ejfv) with KEYTRUDA (pembrolizumab) accelerated approval in the US. |
Competitor Comparison
| Key Parameters | Seagen Inc | F. Hoffmann-La Roche Ltd | Merck & Co Inc | Sanofi | AstraZeneca Plc |
|---|---|---|---|---|---|
| Headquarters | United States of America | Switzerland | United States of America | France | United Kingdom |
| City | Bothell | Basel | Kenilworth | Paris | Cambridge |
| State/Province | Washington | - | New Jersey | Ile-de-France | England |
| No. of Employees | 3,256 | 103,605 | 72,000 | 87,994 | 89,900 |
| Entity Type | Private | Public | Public | Public | Public |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Felix J. Baker, Ph.D. | Chairman | Executive Board | 2022 | 54 |
| David R. Epstein | Chief Executive Officer; Director | Executive Board | 2022 | 61 |
| Todd E. Simpson | Chief Financial Officer | Senior Management | 2005 | 62 |
| Jean I. Liu | Chief Legal Officer | Senior Management | - | 54 |
| Roger D. Dansey, M.D. | Chief Medical Officer; President - Research and Development | Senior Management | 2022 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward